Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: a randomised study
- Conditions
- SchizophreniaMental and Behavioural Disorders
- Registration Number
- ISRCTN27750123
- Lead Sponsor
- niversity of Cologne (Germany)
- Brief Summary
2014 Results article in https://pubmed.ncbi.nlm.nih.gov/24628830/ (added 01/09/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1. Patients with schizophrenia, schizophreniform or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (295.xx) and International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10) (F20, F23.2, F25) as well as cannabis abuse or dependence according to DSM-IV (305.20, 304.30) and ICD-10 (F12.1, 12.2)
2. Capable of giving written informed consent
1. Other relevant neuropsychiatric disorders
2. Prominent (acute) positive symptoms at the timepoint of inclusion
3. Previous treatments with ziprasidone or clozapine with significant side effects
4. No availability of a family member or significant other for the collateral interviews of the follow-up evaluation
5. No compliance with the requirements of the study/lack of or questionable capability of giving informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Amount of cannabis consumption 12 months after inclusion in the study<br> 2. Less side effects in ziprasidone group<br> 3. After 12 months:<br> 3.1. Better compliance in ziprasidone group<br> 3.2. Better course of schizophrenia within the ziprasidone group<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Amount of cannabis consumption 3 and 6 months after inclusion in the study<br> 2. Others compared with primary outcomes just to 3 and 6 months<br>